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Abstract
Introduction—PrEP and Treatment-as-Prevention (TasP) are biomedical strategies to reduce 
HIV transmission. Some men who have sex with men (MSM) are combining biomedical strategies 
with HIV serosorting–termed “biomed matching” when both partners are either on PrEP or TasP, 
or “biomed sorting” when one partner is using PrEP and the other TasP. Nevertheless, there is 
limited data on the extent of biomed matching/sorting in large geographically diverse samples.
Method—In 2016-2017, 5,021 MSM from across the US were surveyed about their HIV status 
and HIV viral load/PrEP use, as well as that of their recent casual male partners. For each 
participant, we calculated the proportion of his partners who were (1) HIV-positive and 
undetectable, (2) HIV-positive and detectable/unknown, (3) HIV unknown/undiscussed, (4) HIV-
negative on PrEP, (5) HIV-negative, not on PrEP.
Results—In total, 66.6% (n=3346) of participants were HIV-negative and not on PrEP, 11.9% 
(n=599) on PrEP, 14.1% (n=707) HIV-positive and undetectable, 1.1% (n=55) HIV-positive and 
viral load detectable/unknown, and 6.2% (n=313) HIV unsure/unknown. A participant’s own HIV 
and PrEP status/was significantly associated with that of his partners (all p<.001), evincing 
evidence of both serosorting and biomed matching. Among men on PrEP and those who were 
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HIV-undetectable, there was also some evidence to suggest these participants dually engaged in 
biomed matching as well as biomed sorting.
Discussion—We found evidence of biomed matching and sorting, which may compound its 
effectiveness for those using it (i.e., both partners bring biomedical protection). Unintended 
consequences of biomed matching/sorting include that men not using a biomedical strategy may 
be less likely to benefit from a partner’s use of the strategy—potentially further driving disparities 
in HIV infections. Public health campaigns might be well served to highlight not only the benefits 
that biomedical HIV prevention strategies provide for their users (e.g., “being on PrEP protects me 
from getting HIV”), but also the benefits that a user brings to his partners (e.g., “my use of PrEP 
means my partners won’t get HIV”), and the benefits of being with a partner who is using a 
biomedical strategy (e.g., “my partner’s use of PrEP/TasP protects me from HIV”).
Keywords
Serosorting; men who have sex with men; Pre-Exposure Prophylaxis (PrEP); Treatment as 
prevention (TasP); HIV
INTRODUCTION
Gay, bisexual, and other men who have sex with men (MSM) remain a critical population at 
risk for HIV/AIDS1–4 with new infections on the rise.5–7 In 2016, the CDC noted that if 
current infection rates persist, one in six MSM will be diagnosed with HIV during their 
lifetimes, and, more specifically, one in two Black MSM and one in four Latino MSM.8 
MSM have adopted a variety of strategies in the decades since HIV was discovered, broadly 
referred to as ‘seroadaption,’ to reduce the risk of transmission.
Seroadaption9–15 describes a diverse set of potentially harm-reducing behaviors that use 
HIV status to inform sexual decision making; examples include seropositioning/strategic 
positioning14,16–18 (selectively practicing insertive or receptive anal sex based on a partner’s 
HIV status), selectively having only oral sex or mutual masturbation,19–21 and serosorting.
14,15,22–27
 Serosorting, specifically, describes a person choosing partners of the same HIV 
serostatus, including to engage in sex without condoms.28–30
Data suggest a diverse set of MSM engage in seroadaptive behaviors, and that such 
behaviors may have increased over time.14,28–30 For example, one study of San Francisco 
MSM found that prevalence of seroadaptive behaviors increased from 36% in 2004 to 47% 
in 2011.31,32 HIV-positive men were more likely to report seroadaptive behavior patterns 
compared to HIV-negative men.14 Studies suggest that serosorting is not as effective at 
reducing HIV transmission as condom use, and some evidence suggests that serosorting may 
actually increase HIV acquisition, depending on community-level HIV prevalence.33 In 
settings with low HIV testing rates, serosorting can more than double the risk of HIV 
acquisition.33
In addition to behavioral strategies, biomedical strategies involving the use of antiretroviral 
medications, can also reduce the risk of HIV transmission. For HIV-positive individuals, 
using antiretroviral therapy (ART) to reduce viral load to undetectable levels greatly reduces 
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infectiousness. One study34 found that reducing the burden of viral load in a given 
community through wide-scale treatment-as-prevention (TasP) could reduce HIV 
transmission at the population level.34,35 In 2016, the Prevention Access Campaign issued a 
consensus statement indicating that individuals with undetectable HIV viral loads present 
negligible risk for HIV transmission to their partners,36 and there has since been consistent 
increasing support that HIV undetectable individuals do not transmit HIV,37,38 including 
endorsement by the CDC.39 Meanwhile, for HIV-negative individuals, anti-retroviral drugs, 
in the form of once-daily Emtricitabine/Tenofovir, have been approved for use in the US as 
HIV pre-exposure prophylaxis (PrEP) since 2012.40–42 PrEP and TasP are among the most 
promising biomedical tools available to prevent HIV transmission.43–46
The extent to which MSM are currently employing combinations of biomedical and 
behavioral strategies to reduce HIV transmission risk has not been well described. Newcomb 
et al.47 introduced the term “biomed matching” to refer to individuals who seek out partners 
who are using the same biomedical prevention strategy (e.g., HIV-negative men on PrEP 
partnering with each other, or HIV-positive men seeking out other virally suppressed 
individuals). Whereas “biomed sorting” (a term that we do not believe has yet been used in 
the literature) more broadly describes individuals who seek out partners who are using a 
biomedical strategy, regardless of whether that strategy is PrEP or TasP (i.e., men on PrEP 
having sex with partners on PrEP or virally suppressed HIV-positive men, and vice versa).48 
In contrast to biomed matching, one can biomed sort without using a biomedical strategy 
themselves (i.e., someone not on PrEP seeking out partners who are on PrEP or using TasP). 
Unintended consequences of biomed matching/sorting include that men not using a 
biomedical strategy may be less likely to benefit from a partner’s use of the strategy—
potentially further driving disparities in HIV infections. Whereas, there are benefits to be 
gleaned when one’s partner uses a biomedical strategy (e.g., his partner is on PrEP or his 
partner his HIV-positive undetectable) even if he is HIV-negative and not using PrEP 
himself. To our knowledge, there have been no published studies explicitly estimating rates 
of biomed sorting and matching. Further, it is also unclear if the use or integration of 
biomedical and behavioral practices vary between HIV-positive and HIV-negative men. Such 
data would be essential to informing public health messages around the benefits that 
biomedical strategies bring to the users themselves (e.g., “PrEP protects me”), as well as 
their partners (“PrEP/TasP protects my partners”), and the benefits of having a partner who 
is using a strategy (“My partner’s use of PrEP/TasP protects me”).
Current Study
Although behavioral HIV risk reduction strategies such as serosorting have been described 
well in the literature, the combined use of seroadaptive and biomedical strategies among 
MSM has not.49–51 To address this gap, we implemented a brief self-administered survey in 
a variety of settings (online, in sexual health clinics, and community-based outreach). We 
report demographic and behavioral differences by HIV status and assess the prevalence of 
various bio-behavioral strategies employed by MSM that could reduce their HIV risk.
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METHOD
Recruitment
Between May 2016 and March 2017, data were collected from participants recruited from 
six different settings. To be eligible, participants had to report being over the age of 18, 
cisgender male, and report sex with a man in the past 5 years.
1. Tablet devices with MSM in clinical settings (e.g., waiting area) of both HIV and 
sexual health clinics in NYC: A variety of methods were used to recruit MSM 
patients in clinical settings (n = 162). These included posted flyers in waiting 
areas, asking providers to refer their patients to the study, and directly 
approaching MSM patients in waiting areas and asking them if they were 
interested in completing an online survey. A privacy screen, which prevents the 
device from being viewed at an angle, was used and we had a separate private 
room available should participants have wanted to complete the survey alone. 
Participants were told that their responses on the survey as well as their 
participation in the project would not be disclosed to their provider.
2. Online, with participants recruited via a sexual networking website or via porn 
websites: For a 30 day period, we hosted a banner advertising the survey on a 
popular men-for-men sexual networking website. The same banner was used on 
the porn websites for a period of 39 days. The ad was restricted to the U.S. Those 
clicking the banner were taken to a separate secure webpage where the survey 
was housed. We generated 934 responses from the sexual networking website 
and 454 from the porn websites.
3. Mobile devices, with participants recruited via a popular geo-social sexual 
networking app: We had one pop-up message that was displayed to participants 
when they opened the app for the first time during a given 12-hour window. We 
generated 1891 responses from eligible participants via this method.
4. Online, with MSM recruited via Facebook. We ran an ad on Facebook for 11 
days. This method generated 454 responses.
5. Tablet devices with MSM recruited in gay neighborhood settings (e.g., gay bars, 
clubs): Teams of two project staff visited gay neighborhoods/spaces (e.g., gay 
bars) and approached patrons to see if they would be interested in completing a 
survey about sexual health. Those interested were handed a tablet device to 
complete the survey alone. This method generated 292 participants.
6. Online with participants from an ongoing cohort study of HIV-negative gay and 
bisexual men. The One Thousand Strong study is following a U.S. national 
sample of 1,071 gay and bisexual men for a period of 3 years. Enrollment for the 
cohort has been described in detail elsewhere,52 but sampling was targeted (using 
census data) such that the distribution of participants in the panel would closely 
mirror that of gay and bisexual men across the U.S, and all participants were 
confirmed to be HIV-negative at enrollment. Participants in One Thousand 
Strong complete online assessments annually; however, the study team also 
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conducted check-in surveys half way between annual assessments to verify 
participant contact information. During the 18-month check-in survey 
participants were offered an opportunity to complete an additional brief online 
survey, in which the measures for this study were embedded. In total, 834 
participants completed this assessment.
Across recruitment methods, participants were informed they were completing a sexual 
health survey. Recruitment materials and the informed consent did not market the study as 
one being about PrEP, serosorting, etc.
Incentives
As an incentive, participants from clinic settings were offered a gift certificate to see a movie 
at a local movie theater. Participants from online settings (adult websites, hook-up website, 
geosocial sexual networking app, Facebook, and the One Thousand Strong cohort) were 
entered into a raffle to win one of fifty $20 amazon gift cards. With the exception of the One 
Thousand Strong cohort, the survey in online settings was anonymous, but participants were 
told they would need to provide an email address if they wanted to be entered into the raffle 
for the gift card. Finally, participants surveyed in gay neighborhood settings were offered 
one scratch off lottery ticket valued at $1 each for completing the survey.
Measures
Participants completed a self-administered computerized survey that took approximately 10 
minutes to complete. The survey itself assessed demographic characteristics as well as 
sexual behaviors for main and casual male partners in the prior three months using the Brief 
Seroadaptive Assessment Tool (B-SAT),53 a brief-intercept self-administered sexual 
behavior data collection method.14,54–57 The B-SAT first asks about sexual behavior with a 
main partner and then separately asks about sexual behavior with casual partners who were 
HIV-positive and undetectable, HIV-positive and not undetectable (or viral load was not 
discussed), HIV-negative and on PrEP, HIV-negative and not on PrEP (or PrEP was not 
discussed), and partners whose status was unknown/not discussed. The B-SAT also assesses 
participant’s HIV status and viral load (if HIV-positive) or PrEP use (if HIV-negative). Study 
procedures were approved by relevant organizational Institutional Review Boards.
Analysis plan
We report (1) demographic differences in the samples across the recruitment venues, 
followed by (2) demographic differences across participants’ HIV status. In so doing, we 
categorized participants’ HIV status into five mutually exclusive groups: HIV-positive and 
undetectable; HIV-positive and detectable or of unknown viral load; HIV-negative and on 
PrEP; HIV-negative and not on PrEP; and HIV status unsure/unknown. Finally, we report the 
extent to which participants were engaged in serosorting and biomed matching. In so doing, 
for each participant HIV-status, we report the proportion of his casual male partners from the 
past 3 months who were (1) HIV-positive and undetectable, (2) HIV-positive and detectable/
unknown, (3) HIV unknown/undiscussed, (4) HIV-negative on PrEP, and (5) HIV-negative, 
not on PrEP. We also compared participants’ HIV status by the total number of casual male 
partners in the previous three months, as well as by the reported HIV status for participants’ 
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main partner (for those in a relationship, n = 2,027). As appropriate, we used ANOVA, chi-
squared, and Kruskal-Wallis tests. Statistical significance was set and α = 0.05 and all 
analyses were conducted in SPSS version 22.
RESULTS
Participants came from all 50 US states plus the District of Columbia and Puerto Rico 
(though the survey itself was in English). First, we report data on how the composition of 
our sample varied by recruitment source (see Table 1). All variables examined differed 
significantly by recruitment venue. Participants from the hook-up website were oldest on 
average (M = 46.1), whereas those via gay neighborhood settings in NYC were youngest on 
average (M = 32.3). Clinic settings had the highest proportion of men of color (84%) 
whereas One Thousand Strong had the lowest (29.1%). Participants recruited via Facebook 
and clinic settings tended to report the least amount of education and those from LGBT 
neighborhood settings tended to report the most education. Participants from the One 
Thousand Strong cohort were the most likely to identify as gay and those from the hookup 
website were the least (95% vs. 71.2%). Participants surveyed via the One Thousand Strong 
cohort (53.8%) and adult websites (52.2%) were among the most likely to report being in a 
relationship, whereas those surveyed via the geosocial sexual networking app were the least 
(30.1%). Finally, participants from clinic settings were the most likely to report being HIV-
positive and undetectable (44.4%) or HIV-negative on PrEP (23.5%) (i.e., using a 
biomedical strategy).
Table 2 reports on demographic differences by participants’ HIV status, all of which were 
statistically significant. HIV-positive and undetectable participants were the oldest on 
average (M = 43.11) and those not knowing their status were the youngest on average (M = 
33.8). HIV-positive and men who said they did not know their HIV status were among the 
most likely to be men of color (49% and 44.7% respectively). Men on PrEP tended to report 
more education than other groups (64.6% had completed college). Men who did not know 
their HIV status were the least likely to identify as gay and the least likely to be in a current 
relationship.
Table 3 reports on HIV serosorting and biomed matching/sorting among participants in the 
sample. Among men who reported casual male sex partners in the prior 3 months, HIV-
negative participants who were not on PrEP reported the fewest partners on average (Mdn = 
3), whereas HIV-positive and undetectable participants and participants on PrEP reported the 
greatest, on average (Mdn = 6). By and large, participants tended to report partners whose 
HIV-status and biomedical strategy matched their own. For example, the proportion of 
casual partners who were HIV-positive and undetectable was significantly higher among 
participants who were themselves HIV-positive and undetectable at 0.28 (versus 0.20 for 
participants who were HIV-positive and detectable, 0.12 among those HIV-negative and on 
PrEP, 0.07 for those HIV-negative and not on PrEP, and 0.08 for participants who did not 
know their HIV status, p < 0.001). The proportion of partners HIV-positive and detectable 
was highest among those who were themselves HIV-positive and detectable at 0.16 (versus 
0.06 for those HIV-positive and undetetable, 0.02 for those HIV-negative on PrEP, 0.01 for 
those HIV-negative and not on PrEP, and 0.02 for participants who did not know their HIV 
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status, p < 0.001). This pattern of “matching” was observed for all five HIV status groups. 
Full results in Table 3.
In contrast to the strong evidence that partcipants were engaging in biomed matching, there 
was some evidence of biomed sorting. In terms of proportions of partners, participants who 
were HIV-positive and undetectable said that 28% of their partners were HIV-positive and 
undetectable (i.e., biomed matched), 27% of their partners were HIV unknown/not 
discussed, and 24% were on PrEP (i.e., biomed sorted). Participants on PrEP said that 41% 
of their partners were on PrEP (i.e., biomed matched), 28% were HIV-negative not on PrEP, 
17% were HIV unknown/not discussed, and 12% were HIV-positive undetectable (i.e., 
biomed sorted). HIV-negative men not on PrEP said that 44% of their partners were also 
HIV-negative and not on PrEP (i.e., serosorting), 26% were HIV unknown, 22% were on 
PrEP (i.e., biomed sorted), 7% were HIV undetectable (i.e., biomed sorted), and 1% were 
HIV-positive and detectable (or viral load not known).
We next examined whether participants had engaged in condomless anal sex (CAS) with 
partners across HIV categories. Overall, HIV-positive participants were more likely to 
engage in CAS than HIV-negative participants; however, HIV-positive participants tended to 
report engaging in CAS more so with HIV-positive partners than compared to HIV-negative 
participants—and HIV-negative participants tended to engage in CAS with other HIV-
negative partners. See Table 3. There was stronger evidence of biomed sorting when it came 
to CAS. HIV-positive undetectable participants tended to report CAS more when their 
partners were also HIV-positive (i.e., biomed matched) as well as when their partners were 
on PrEP (CAS with 31.2% of partners on PrEP; i.e., biomed sorted), as opposed to when 
their partners were HIV-negative and not on PrEP (CAS with 21.6% of these partners) or 
when they did not know the status of their partners (CAS with 24% of these partners). 
Similarly for men on on PrEP, CAS was most common when partners were also on PrEP 
(CAS with 29.4% of these partners; i.e., biomed matched), HIV-negative and not on PrEP 
(CAS with 23.5% of these partners; i.e., serosorting), or HIV-positive and undetectable 
(CAS with 19.4% of these partners; i.e., biomed sorted). Whereas, among men on PrEP, 
CAS was least common when partners were HIV-positive and detectable (9.4%) or when 
partners status was unknown (12.2%). For HIV-negative men not on PrEP, CAS was most 
common when partners were also HIV-negative and not on PrEP (CAS with 12.9% of these 
partners; i.e., serosorting), followed by when partners were on PrEP (CAS with 11% of these 
partners; i.e., biomed sorted), when status was not discussed/unknown (CAS with 8.2% of 
these partners), when partners were HIV-positive undetectable (CAS with 7.1% of these 
partners; ie., biomed sorted), and when partners were HIV-positive but detectable/unknown 
(CAS with 2.9% of these partners).
As with casual male sex partners, there was strong evidence of biomed matching among 
participants in relationships (n = 2027). For example, 35.4% of HIV-positive and 
undetectable participants said their partner was HIV-positive and undetectable (versus 22.4% 
among HIV-negative men on PrEP, 20.0% among HIV-positive and detectable, 4.1% among 
HIV-negative men not on PrEP, and 4.1% among men who did not know their HIV status, p 
< .001). Similarly, 32.9% of men on PrEP said their partner was on PrEP (versus 12.9% 
among HIV-positive undetectable, 8.0% among HIV-positive and detetable men, 1.6% 
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among HIV-negative men not on PrEP, and 1.0% among men who did not know their status). 
And 40.2% of men who said they were unsure of their status said their partner was also 
unsure of his status (versus 14.0% among men who were HIV-negative and not on PrEP, 
12.9% among HIV-positive undetectable men, 8.0% among HIV-positive and detectable 
men, and 7.9% among HIV-negative men on PrEP). Full results are shown in Table 3.
DISCUSSION
We found strong evidence that not only were participants engaging in serosorting (having 
sex with partners of the same perceived HIV status), but also—for those taking advantage of 
a biomedical strategy—engaging in biomed matching. That is, HIV-positive undetectable 
participants comprised 14.1% of the sample, yet they indicated that 28% of their casual 
partners were HIV-positive undetectable. Meanwhille, 35% of HIV-positive undetectable 
participants who were in relationships said their partner was also HIV-positive undetectable. 
Similarly, men on PrEP comprised 11.9% of participants, yet reported that 41% of their 
casual male partners were on PrEP. And, 33% of the participants on PrEP who were in a 
relationship said their partner was also on PrEP. Meanwhile, compared with others, men not 
utilizing a biomedical strategy more often partnered with men also not using a biomedical 
strategy. Among men on PrEP and those who were HIV-undetectable, there was also some 
evidence to suggest these participants dually engaged in biomed matching as well as biomed 
sorting. Both biomed sorting and biomed matching may compound their effectiveness for 
those using it (i.e., both partners bring biomedical protection).47 However, this also means 
that men not using a biomedical strategy may be less likely to benefit from a partner’s use of 
the strategy—potentially further driving disparities in HIV infections in certain 
subpopulations with lower access to or uptake of biomedical prevention.
We also found that, in addition to partnering with men who shared the same HIV status, 
participants also tended to report engaging in CAS more so with partners who were believed 
to share the same HIV status. For men using a biomedical strategy, the risk for HIV 
transmission during these encounters may be negligible; however, for those not using a 
biomedical strategy, there may be additional risk for HIV transmission. Compared to other 
groups, HIV-negative men not on PrEP were the least likely to report CAS; however, when 
CAS did occur among these participants, it was most often with a partner believed to be 
HIV-negative and also not on PrEP. If undiagnosed and untreated HIV infection is higher 
among this group, this could significantly potentiate HIV transmission during CAS. Some 
research has suggested that serosorting is not as effective at reducing HIV transmission as 
condom use, and some evidence suggests that serosorting may actually increase HIV 
acquisition.33 This may be due to low HIV testing rates/frequency,33 yet partners still report 
they are HIV-negative.
We also reported demographic differences by the venue in which participants were surveyed. 
Similar to what others have reported,56,58–63 participant characteristics were associated with 
where participants were recruited. For both providers and researchers, these findings further 
highlight the need to focus efforts (whether for recruitment, interventions, health education 
messages) within different venues to reach diverse populations. In our study, men of color 
were most likely to have been identified via clinic settings (likely an artifact of who the 
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clinics served), men via gay neighborhood settings (e.g., bars) were youngest on average, the 
greatest proportion of men who did not know their HIV status were identified via the social-
sexual networking app, and the greatest proportion of men who did not identify as gay were 
enrolled via the hook-up website. Researchers and providers seeking to reach younger MSM 
might be well served to conduct outreach in gay neighborhood settings. Likewise, those 
seeking to engage with MSM who do not know their HIV status might be well served to 
conduct outreach via social-sexual networking apps, and those seeking to engage with non-
gay-identified MSM might be well served to conduct outreach via hook-up websites. In 
addition to knowing which venue to go to in order to engage a particular population (e.g., 
where to go), these findings also inform the types of messages that might be more 
appropriate in different venues (e.g., how to market one’s message).
Limitations
The findings of this study should be understood in light of its limitations. The B-SAT is a 
self-administered assessment tool that can be used in both research and clinical settings to 
assess for HIV risk among MSM. However, it focuses on sexual behavior in the prior 3 
months, whereas CDC recommendations for PrEP indication assesses for sexual behavior 
over the prior 6 months.64 Thus although the B-SAT could be used to identify men who 
would be appropriate candidates for PrEP, it is limited in that there could be men whose 
behavior between 3 and 6 months ago would suggest PrEP is indicated, but their more recent 
behavior (within the last 3 months, as captured on the B-SAT) could suggest that PrEP is not 
indicated. In addition, the B-SAT does not capture motivation or intent, only past behavior. 
In an effort to be brief, it also does not capture withdrawal before ejaculation during CAS, 
nor does it capture behavior with female or transgender partners.
Responses on our survey were self-report and, for many of our participants, anonymous. We 
believe we found evidence of serosorting as well as biomed matching, both of which have 
been documented in prior research.9–14,22–27,47 However, we do not know the actual HIV 
statuses of participants’ partners, and it may be that participants believed their partners 
shared the same status. In online venues, our ads were targeted to reach MSM, but it is 
possible that some responses were collected from participants who might have 
misrepresented their data. Our survey was programmed to record IP address as well as block 
multiple submissions from a given IP address and our incentives were low and not 
guaranteed (i.e., a raffle) such to disincentivize fraudulent participants. Next, our analyses 
did not control for confounders. Finally, we are unable to calculate a response rate for our 
survey and cannot attest as to whether those who chose to participate characteristically 
differed from those who did not.
Conclusion
As opposed to picking partners at random (i.e., regardless of a partners’ HIV status/
biomedical strategy), our findings indicate that participants gravitated toward partners who 
share the same HIV status and—in the case of those using a biomedical prevention strategy
—the same biomedical HIV prevention or treatment strategy. Furthermore, CAS events were 
also more common when a partner shared the same HIV status. When two partners both use 
a biomedical HIV prevention strategy, its effectiveness could be compounded (i.e., both 
Grov et al. Page 9
AIDS Behav. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
partners bring biomedical protection). One consequence of biomed matching, however, is 
that men not using a biomedical strategy would be less likely to benefit from the protection 
that a partner using a biomedical strategy would bring to the sexual encounter. With the 
continued rollout of PrEP as well as the dissemination of new data regarding 
untransmisibility of HIV among HIV-positive and undetectable individuals,36,39 our findings 
highlight the need for researchers to investigate both serosorting and biomedical sorting/
matching as well as their impact on ongoing HIV disparities. That is, an unintended 
consequence of biomedical prevention strategies is that they may further contribute to racial 
disparities in HIV. Public health campaigns might be well served to highlight not only the 
benefits that biomedical HIV prevention strategies provide for their users (e.g., “being on 
PrEP protects me from getting HIV”), but also the benefits that a user brings to his partners 
(e.g., “my use of PrEP means my partners are protected from HIV”), and the benefits of 
being with a partner who is using a biomedical strategy (e.g., “my partner’s use of PrEP/
TasP protects me from HIV”).
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